Mol Cell:研究人员找出炎症反应关键调节因子

2012-04-14 Beyond 生物谷

近日,美国波士顿大学医学院(BUSM)研究人员已经发现一种基因在调节炎症反应和内环境稳态中起着关键作用。这些发现可能有助于开发出减少癌症、2型糖尿病和其他疾病相关的炎症。   BUSM生物化学助理教授Valentina Perissi博士带领的研究团队与圣迭戈加利福尼亚大学霍华德·休斯医学研究所(HHMI)合作共同完成该项研究。研究结果发表在Molecular Cell杂志上。 &

近日,美国波士顿大学医学院(BUSM)研究人员已经发现一种基因在调节炎症反应和内环境稳态中起着关键作用。这些发现可能有助于开发出减少癌症、2型糖尿病和其他疾病相关的炎症。

 

BUSM生物化学助理教授Valentina Perissi博士带领的研究团队与圣迭戈加利福尼亚大学霍华德·休斯医学研究所(HHMI)合作共同完成该项研究。研究结果发表在Molecular Cell杂志上

 

细胞受炎症反应刺激产生细胞因子,细胞因子是细胞间沟通的信号蛋白分子。细胞因子(如本文系梅斯医学(MedSci)原创编译整理,转载需授权!-->

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958704, encodeId=fa861958e049d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 02 23:32:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907400, encodeId=0d30190e4008e, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Nov 23 16:32:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969245, encodeId=b6fe1969245bf, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 12 04:32:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868490, encodeId=45d518684902c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Mar 25 03:32:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320794, encodeId=df901320e9481, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Apr 15 15:32:00 CST 2012, time=2012-04-15, status=1, ipAttribution=)]
    2012-08-02 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958704, encodeId=fa861958e049d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 02 23:32:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907400, encodeId=0d30190e4008e, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Nov 23 16:32:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969245, encodeId=b6fe1969245bf, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 12 04:32:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868490, encodeId=45d518684902c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Mar 25 03:32:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320794, encodeId=df901320e9481, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Apr 15 15:32:00 CST 2012, time=2012-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958704, encodeId=fa861958e049d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 02 23:32:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907400, encodeId=0d30190e4008e, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Nov 23 16:32:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969245, encodeId=b6fe1969245bf, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 12 04:32:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868490, encodeId=45d518684902c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Mar 25 03:32:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320794, encodeId=df901320e9481, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Apr 15 15:32:00 CST 2012, time=2012-04-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958704, encodeId=fa861958e049d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 02 23:32:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907400, encodeId=0d30190e4008e, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Nov 23 16:32:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969245, encodeId=b6fe1969245bf, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 12 04:32:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868490, encodeId=45d518684902c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Mar 25 03:32:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320794, encodeId=df901320e9481, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Apr 15 15:32:00 CST 2012, time=2012-04-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958704, encodeId=fa861958e049d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 02 23:32:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907400, encodeId=0d30190e4008e, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Nov 23 16:32:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969245, encodeId=b6fe1969245bf, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 12 04:32:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868490, encodeId=45d518684902c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Mar 25 03:32:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320794, encodeId=df901320e9481, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Apr 15 15:32:00 CST 2012, time=2012-04-15, status=1, ipAttribution=)]

相关资讯

糖尿病杂志中文导读第一期(2011.3)

糖尿病杂志中文导读第一期(2011.3)

2012年01-02月 Nature亮点研究汇总

2012年01—2012年02月Nature亮点研究整理版 大脑对奖励的反应 Neuron-type-specific signals for reward and punishment in the ventral tegmental area 1月18日,美国物理学家组织网报道,美国科学家绘制出了迄今最完整的大脑神经相互作用以增强从学习到服药等行为的图谱,有望为科学家们治疗成瘾开辟新道路

MedSci专家评论:抗衰老研究面面观

    抗衰老总是处于风口浪尖的话题,而且社会上经常出现所谓的“抗衰老药物”,或所谓的抗衰老组织,有些能自称“世界XXX”或“科学院”等让人景仰的名称来吸引人注意,甚至赢得公众的信任。那么抗衰老到底为何物?是骗子还是科学?MedSci给你解析: 一、抗衰老的三种社会态度     提到抗衰老,总有三种声音。一种是:肯定是骗子,衰老是难以

争鸣:医学研究结果为何难以重复?

两年前,波士顿的一组研究人员发表了一篇论文,描述他们是如何通过一种叫STK33的靶点蛋白来消灭癌症肿瘤的。总部位于加州绍曾德奥克斯 (Thousand Oaks)的生物技术公司Amgen Inc.的科学家迅速跟进,安排了二十多名研究人员尝试重复这个实验,期望能研发出一种相关药物。 拜耳公司的研究人员发现,内部试验经常无法重现文献结论。而事实证明他们既浪费了时间,也浪费了金钱。经过六个月深入细致的

J Nati Cancer I:麦海强等鼻咽癌研究取得新进展

近日,国际著名杂志Journal of the National Cancer Institute 刊登了中山大学肿瘤防治中心鼻咽科麦海强教授等的最新研究成果“Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial。”在文章

Journal Watch 2011心脏病热门研究

  近日,《新英格兰医学杂志》旗下的Journal Watch网站公布了由编辑挑选的2011心脏病热门研究。   包括:   1、缺血性左室收缩功能不全患者CABG或药物治疗   冠状动脉旁路移植术(CABG)或可在某种程度减少缺血性左室收缩功能不全(LVSD)患者的不良转归,但并未延长生命。   2、经导管主动脉瓣置入:高危手术的理想替代选择?   经导管主动脉瓣置入(TAVI)在短期